Plain-English translation of NCT06831825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new genetic medicine called YAP101 that is injected directly into the heart muscle. The medication is designed to trigger the heart's natural ability to repair and regenerate itself after a heart attack, potentially improving how well the heart pumps blood throughout the body.
Heart failure caused by heart attacks is a serious condition that current treatments can only manage—they don't help the heart actually heal itself. This trial exists because researchers believe this medication could fill that gap by helping damaged heart tissue regenerate and repair on its own.
You likely qualify if…
You likely don't qualify if…
You would receive a one-time injection of the medication directly into your heart muscle using a cardiac catheter (a thin tube guided to the heart). After the injection, you would return for regular outpatient visits over 12 months to have your heart monitored through MRI scans, blood tests, and exercise and quality-of-life assessments. If the study goes well, you would have the option to continue being followed for up to 5 additional years.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States